Incyte lands priority review for PD-1 inhibitor in anal cancer

Incyte lands priority review for PD-1 inhibitor in anal cancer

Submitted by admin on January 22, 2021 - 10:31am
Source: 
Fierce Biotech
News Tags: 
Incyte
FDA
priority review
anal cancer
retifanlimab
Headline: 
Incyte lands priority review for PD-1 inhibitor in anal cancer
snippet: 

The FDA has accepted Incyte’s PD-1 inhibitor retifanlimab for priority review in patients with locally advanced or metastatic squamous cell carcinoma of the anal canal (SCAC).

Do Not Allow Advertisers to Use My Personal information